Tizanidine Hydrochloride Capsule, Gelatin Coated
Product Images NDC 60505-2649

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 60505-2649). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2mg-150btl (2mg 150btl)

This appears to be medication packaging information for Tizanidine Hydrochloride Capsules. Each capsule contains 2.288 grams of Tizanidine Hydrochloride USP and 0.192 grams of Zanaflex. The capsules should be stored between 68 and 77 degrees Fahrenheit, and should be dispensed in a high-density container with a child-resistant closure. The recommended dosage should be followed according to the package instructions. Zanaflex is a registered trademark of Acorda Therapeutics. The package contains 150 capsules and has an NDC number of 60505-2648-7.*

FDA Label Image

4mg-150btl (4mg 150btl)

Each capsule of Tizanidine Hydrochloride contains 4576mg of Tizanidine and is a USP (substance). It also contains 194g of zandin base. It is stored at a controlled temperature of 50°C (8°F) and has a limited prescription of 558 USP Corirollsd Foom Temperstur. It is dispensed in containers with instand colors and dosage should be as per package instruction. Tizanidine is a registered trademark of Acorca Therapeutcs. The given text seems to be a packaging label of a medicine with 150 capsules.*

FDA Label Image

6mg-150btl (6mg 150btl)

This appears to be a label of medication containing Tizanidine Hydrochloride Capsules. Each container has 150 capsules with a usual dosage mentioned on the package. The USP (United States Pharmacopeia) is mentioned with the weight of the medicine. The package has a registered trademark of Acorca Therapeutcs with a specific NDC (National Drug Code) for regulating the drug in the USA. The rest of the text seems to be technical information regarding dispensing and storing the medication.*

FDA Label Image

Chemicalstructure (Chemical Structure)

FDA Label Image

Figure2 (Figure 2)

FDA Label Image

Figure3 (Figure 3)

The text describes an improvement in Ashworth Score through the use of Tizanidine, with a mean dose of 26.8 mg. The study used an end of titration, end of maintenance, and endpoint approach, with observations conducted during week 3 and week 7.*

FDA Label Image

Figure1 (Figure1)

This text seems to be displaying a timeline that represents different hours after a medication (T2) has been administered. The hours displayed are 14, 16, and 18. The term "Hours from Dosing" indicates that these hours represent the time elapsed since the medication was administered. The number 0 could possibly represent the initial moment when the medication was administered, but more context is needed to conclude that with confidence.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.